It is unknown whether favorable HLA class II alleles may attenuate HIV-1 through selection pressure in a manner similar to that of protective HLA class I alleles. We investigated the relationship between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals. No associations were found between individual alleles and lower replication capacity, suggesting no significant HIV-1 attenuation by HLA class II-restricted Gag-specific CD4(+) T cell immune pressure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255856 | PMC |
| http://dx.doi.org/10.1128/JVI.06533-11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HLA-E: Immune Receptor Functional Mechanisms Revealed by Structural Studies.
Immunol Rev
January 2025
Nuffield Department of Medicine, Center for Immuno-Oncology, University of Oxford, Oxford, UK.
HLA-E is a nonclassical, nonpolymorphic, class Ib HLA molecule. Its primary function is to present a conserved nonamer peptide, termed VL9, derived from the signal sequence of classical MHC molecules to the NKG2x-CD94 receptors on NK cells and a subset of T lymphocytes. These receptors regulate the function of NK cells, and the importance of this role, which is conserved across mammalian species, probably accounts for the lack of genetic polymorphism.
View Article and Find Full Text PDFCorporate genome screening India (CoGsI) identified genetic variants association with T2D in young Indian professionals.
Sci Rep
January 2025
NMC Genetics India Pvt. Ltd., Gurugram, Haryana, 122001, India.
Rising cases of type 2 diabetes (T2D) in India, especially in metropolitan cities is an increasing concern. The individuals that were most affected are young professionals working in the corporate sector. However, the corporate sector has remained the least explored for T2D risk predisposition.
View Article and Find Full Text PDFAssessing the Predictive Power of PIRCHE-II Scores for the Development of Donor-Specific Antibodies After Simultaneous Pancreas-Kidney Transplantation.
Transpl Int
January 2025
Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.
The molecular HLA epitope mismatch is an advanced measure for developing donor-specific antibodies (dnDSA) after kidney transplantation. Its relevance in simultaneous pancreas/kidney transplant recipients (SPKTRs) remains unclear. We investigated dnDSA development in 72 SPKTRs and 383 kidney transplant recipients (KTRs) and used the Predicted Indirectly Recognizable HLA-Epitopes (PIRCHE-II) algorithm to calculate the mismatch load of HLA-derived epitopes in total, per HLA-class, and per HLA-locus.
View Article and Find Full Text PDF[Establishment and Application of Efficient Gene Editing Method for Classical HLA-I Molecules].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou 310052, Zhejiang Province, China.
Objective: To establish an efficient gene editing method of HLA-I gene to prepare HLA-I universal hematopoietic stem cells.
Methods: The easyedit small guide RNA(sgRNA) was designed according to the sequences of β2 microglobulin gene and synthesized by GenScript company. RNP complexes were formed by NLS-Cas9-NLS nuclease and Easyedit sgRNA according to different molar ratios (1∶1~1∶4).
Optimized GVHD Prevention in HLA-Mismatched Unrelated Allogeneic HCT Using a PTCY-Based Approach.
Eur J Haematol
December 2024
Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.
Although post-transplant cyclophosphamide (PTCY)-based prophylaxis has become a widely adopted strategy for preventing graft-versus-host disease (GVHD) in 9 out of 10 HLA-mismatched unrelated donors (MMUDs), allogeneic hematopoietic cell transplants (allo-HCTs), data on the safety and efficacy of PTCY in this setting remain limited. This single-center study investigates the outcomes of 94 adults with hematological malignancies undergoing MMUD allo-HCT with PTCY and tacrolimus (Tac) (PTCY-Tac) between 2014 and 2023. The median age was 53 years, and 60.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!